Glenmark's post-marketing surveillance shows no safety concerns on use of Favipiravir for COVID-19
2 min read
fairly difficult
New Delhi [India], September 15 (ANI): The Glenmark Pharmaceuticals' post-marketing surveillance (PMS) study has shown no safety concerns with the use of...
Representive Image

By Shalini Bhardwaj

Favipiravir (FabiFlu®[?]) in India for COVID-19 infection.

Favipiravir (FabiFlu®[?]) was used to treat patients with moderate to mild COVID-19 infection.

According to the research-led and global integrated pharmaceutical company, the PMS study was done on 1083 patients at multiple centres. The purpose of the study was to evaluate the safety and efficacy of Favipiravir in mild to moderate COVID-19 patients.

The results showed no safety concerns with the use of Favipiravir, the statement issued by Glenmark Pharmaceuticals said.

"Results showed no new safety signals or concerns with the use of Favipiravir, and already-known side effects such as weakness,…
Read full article